Challenges Around Access to and Cost of Life Saving Medications after Allogeneic Hematopoietic Cell Transplantation for Medicare Patients

Highlights • Prescription medicine coverage for HCT for some Medicare beneficiaries, especially those with multiple post HCT complications is a source of financial burden for these low fixed income patients. • Individual and policy level changes may need to occur to provide long-term affordable care...

Full description

Saved in:
Bibliographic Details
Published in:Biology of blood and marrow transplantation 2017-08, Vol.23 (8), p.1387-1392
Main Authors: Farnia, Stephanie, MPH, Ganetsky, Alex, Pharm D, Silver, Alicia, MPP, Hwee, Theresa, Preussler, Jaime, MS, Griffin, Joan, PhD, Khera, Nandita, MD MPH
Format: Article
Language:English
Subjects:
Aged
Allografts
Costs and Cost Analysis
Female
Financial burden
Health Services Accessibility - economics
Hematologic Diseases - economics
Hematologic Diseases - therapy
Hematology, Oncology and Palliative Medicine
Hematopoietic cell transplantation
Hematopoietic Stem Cell Transplantation - economics
Humans
Male
Medicare
Medicare - economics
Prescription coverage
Prescription Drugs - economics
United States
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Prescription medicine coverage for HCT for some Medicare beneficiaries, especially those with multiple post HCT complications is a source of financial burden for these low fixed income patients. • Individual and policy level changes may need to occur to provide long-term affordable care to HCT patients to avoid poor clinical and financial outcomes.
ISSN:1083-8791
1523-6536
DOI:10.1016/j.bbmt.2017.04.010